Celltech

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Celltech Group
Public
IndustryBiotechnology
FateAcquired
SuccessorUCB
Founded1980
Defunct2004
HeadquartersSlough, UK
Key people
Goran Ando (CEO)

Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index.

History[edit]

The Company was founded by Gerard Fairtlough in 1980 with finance from the National Enterprise Board.[1]

In 1999 the Company led consolidation in the UK biosciences market merging with Chiroscience plc and then buying Medeva plc.[2] Then in 2000 it bought Cistron, a US biosciences business.[3] It expanded into Germany in 2001 buying Thiemann, a German biosciences business,[4] and went on to buy Oxford Glycosciences in July 2003 for £102m.[5] Celltech was acquired by UCB, a Belgian drugmaker, in 2004.[6] Since then it has been known as UCB Celltech.

Operations[edit]

The Company was engaged in research and development of therapies for patients with serious diseases. Products included:[7]

See also[edit]

References[edit]

  1. ^ Pharmatelevision
  2. ^ UK Biotech Industry Consolidates As Celltech Buys Medeva for $915m[permanent dead link]
  3. ^ UK's Celltech Buys Cistron of the US[permanent dead link]
  4. ^ Celltech acquires German sales and marketing firm Thiemann for $44.6 mill
  5. ^ ISIS Archived September 17, 2014, at the Wayback Machine.
  6. ^ "Celltech sold to Belgian firm in £1.5bn deal". The Guardian. 18 May 2004.
  7. ^ Businessweek: Celltech Group Archived September 8, 2012, at the Wayback Machine.
  8. ^ Damle, NK; Frost, P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in Pharmacology. 3 (4): 386–90. doi:10.1016/S1471-4892(03)00083-3. PMID 12901947.